Loading... Today
-- 0
-- 0
Join Groups & Channels, No Spamming
Mr. Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla Limited, said the company delivered its highest-ever first-quarter revenue of Rs. 7,119 crore in Q1 FY27, supported by strong growth in One India, new product launches and continued expansion across chronic, specialty and wellness segments. Cipla is strengthening its North America portfolio with new launches, including generic Ventolin, Nintedanib and Dapagliflozin, while preparing four significant launches for the remainder of the year. The company is also increasing investments in upcoming product launches and manufacturing readiness, with R&D spending at Rs. 486 crore during the quarter.
The Print Times
Mr. Achin Gupta – Managing Director and Global Chief Executive Officer, Cipla Limited, said Cipla delivered its highest-ever Q1 revenue of Rs. 7,119 crore in the first quarter of FY27, representing a 2% year-on-year increase. He said the record first-quarter performance provides a strong start to the year and reinforces the resilience and diversified nature of Cipla's business fundamentals.
Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 74 markets providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
Gupta highlighted the strong performance of the company's One India business, which achieved its highest-ever quarterly revenue with 12% year-on-year growth. The branded prescription business delivered market-leading growth of 15.4%, according to IQVIA data, supported by strong momentum across chronic therapies.
Key therapies recorded strong growth, with respiratory growing 15%, anti-diabetes 43%, cardiac 20% and urology registering double-digit growth. According to Gupta, the performance was driven by volume expansion, sustained brand strength, focused field execution and continued momentum from new product launches.
Cipla's chronic mix strengthened to 60.4%, while two new brands entered the Rs. 100-crore-plus club, taking the total to 33. The company also has 23 brands among the IPM's top 300 brands. Foracort continued to maintain its position as the No. 1 respiratory brand in the IPM and remained a Rs. 1,000-crore-plus franchise.
Gupta also highlighted Cipla's continued new product and portfolio expansion, with targeted launches across chronic, specialty and wellness segments. These included Duolin Synchrobreathe and Bilafav M in respiratory care, Yurpeak in obesity, UPADACIP in immunology and Byefilm in nasal hygiene.
In the North American market, Cipla reported quarterly revenue of US$162 million and maintained a 21% market share in the overall U.S. Albuterol MDI market. Gupta highlighted the successful launch of generic Ventolin, with commercial shipments already commenced and volumes expected to increase as supply scales up.
The company also launched Nintedanib and Dapagliflozin, alongside recent launches such as Liraglutide, strengthening its presence in high-growth therapy areas.
Gupta said Cipla's North America pipeline for the remainder of FY27 includes four significant launches, comprising three respiratory assets, including generic Advair, and a key peptide opportunity. Two respiratory assets have been filed from U.S. manufacturing facilities and the third from the Goa facility.
The company is also investing in manufacturing readiness and future product launches. Total expenses stood at Rs. 3,260 crore, with the sequential increase reflecting planned investments in upcoming product launches and enhancement of manufacturing readiness. R&D expenditure stood at Rs. 486 crore, or 6.8% of revenue, primarily directed towards product filings and key development programmes.
Cipla reported an EBITDA margin of 16.7%, excluding other income, while gross margin after material costs stood at 62.5%. Profit after tax was Rs. 789 crore, representing 11% of sales.
Gupta said Cipla would continue to focus on strengthening chronic therapies and respiratory in India, driving growth through new product introductions in North America, outperforming the market in South Africa and maintaining top-line growth with a strong margin trajectory in EMEU.
Overall, Mr. Achin Gupta said Cipla's focus remains on innovation, portfolio expansion, new product launches, manufacturing readiness and execution across key markets, positioning the company for sustained long-term growth.
.webp)
Join WhatsApp Group
Join Telegram Channel
Join YouTube Channel